sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
agacuggcuuugcagaaga | 1122 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cuggggcaguggacaacag | 2796 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucuauaguaaaaacauag | 3329 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugcccauucuuaucccgaa | 3479 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugcccauucuuaucccgaa | 517 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugcccauucuuaucccgaa | 3634 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaccaccugccccagcacc | 1740 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
agcacgaggaaaacaagag | 1844 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aguguccauaacugcccca | 1684 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gccgguucacaguuuuaaa | 1502 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugcccuggcuuguggcagg | 1020 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uuugcagcaguucucugag | 2122 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaaaucucacagccuggca | 1956 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ugcagugcccuggcuugug | 1030 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ucccauggaggucugccag | 1824 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
acacucuuucuggucuuug | 295 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aaggugauugcuccaaacu | 2270 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
caccccagaugaugaacua | 2963 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uguccauucaauggauggg | 2197 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaaaaacucgauaggugug | 1472 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cucuuucacucaucacuuc | 3110 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
augggccacaucacacagc | 2238 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
uaacugccccacacacccg | 1670 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ccuggaaguucuucagcag | 1224 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
acuuaaccccaggccauua | 3229 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ucugauucugggaaccaug | 1991 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cugaagagcgcugagggac | 2665 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
acuuuggcacucggcuguu | 2066 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aucccgagucccccaggcc | 625 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
guggacaaugcccgagggg | 816 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cugauucugggaaccaugc | 1993 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
ucacauauaaagacaacuc | 267 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cauuaguucaucacagacu | 2880 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
caucaucuuagccagggug | 1924 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aggcuugagcaaguuggua | 260 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cucggcuguuucgaauccc | 2048 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
aguaaauuccauguggacu | 1801 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
cccauggaggucugccagc | 1822 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
gaccacaccuaucgaguuu | 366 | US11028392B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | 20,210,608 | 3 | [
"CL",
"ZA",
"MX",
"IL",
"IT",
"HK",
"SK",
"TW",
"TR",
"CA",
"CY",
"MY",
"AU",
"KR",
"AR",
"EE",
"DO",
"US",
"LT",
"IN",
"GC",
"HU",
"JP",
"AT",
"UA",
"EP",
"NZ",
"WO",
"BR",
"PH",
"SG",
"SI",
"EA",
"OA",
"PT",
"HR",
"CN",
"ID",
"NO",
"DK"... | null |
tcatataaactgctagcatgtct | 2318 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcatataaactgctagcatgtct | 2318 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcatataaactgctagcatgtct | 2318 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcatataaactgctagcatgtct | 3383 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcatataaactgctagcatgtct | 3383 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcatataaactgctagcatgtct | 3383 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgccaaatatatgaattctagg | 2657 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgccaaatatatgaattctagg | 2657 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttgccaaatatatgaattctagg | 2657 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 2352 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 2352 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 2352 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 3417 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 3417 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taaacaagaaacttaccatttct | 3417 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgctgtggatattgttgtggctt | 1174 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgctgtggatattgttgtggctt | 1174 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgctgtggatattgttgtggctt | 1174 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggatgtgttcatgaaaggact | 1146 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggatgtgttcatgaaaggact | 1146 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggatgtgttcatgaaaggact | 1146 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 2184 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 2184 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 2184 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 3249 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 3249 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tctaatgaattcctttacaccac | 3249 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2543 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2543 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2543 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2765 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2765 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gtattcatgaaaggactttcaaa | 2765 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 509 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 509 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 509 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 779 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 779 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 779 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 2983 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 2983 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 2983 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 329 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 329 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 329 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 1918 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 1918 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 1918 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 59 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 59 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagttgttagtgatttgctaa | 59 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 3520 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 3520 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 3520 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 2455 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 2455 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tatcctagaattcatatatttgg | 2455 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgtgtggtttggtattccaagtg | 732 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgtgtggtttggtattccaagtg | 732 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgtgtggtttggtattccaagtg | 732 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgtgtggtttggtattccaagtg | 282 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.